Insmed (INSM) Competitors $136.02 +1.49 (+1.11%) As of 12:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INSM vs. GSK, TAK, ARGX, ONC, BNTX, TEVA, SMMT, GMAB, VTRS, and RDYShould you be buying Insmed stock or one of its competitors? The main competitors of Insmed include GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. Insmed vs. Its Competitors GSK Takeda Pharmaceutical argenex BeOne Medicines BioNTech Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Viatris Dr. Reddy's Laboratories GSK (NYSE:GSK) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership. Which has more risk and volatility, GSK or INSM? GSK has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Insmed has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Is GSK or INSM more profitable? GSK has a net margin of 10.81% compared to Insmed's net margin of -259.82%. GSK's return on equity of 49.22% beat Insmed's return on equity.Company Net Margins Return on Equity Return on Assets GSK10.81% 49.22% 11.31% Insmed -259.82%-195.37%-49.49% Does the media prefer GSK or INSM? In the previous week, GSK had 6 more articles in the media than Insmed. MarketBeat recorded 40 mentions for GSK and 34 mentions for Insmed. Insmed's average media sentiment score of 0.93 beat GSK's score of 0.60 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 14 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Insmed 16 Very Positive mention(s) 7 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer GSK or INSM? GSK currently has a consensus target price of $37.38, indicating a potential downside of 5.68%. Insmed has a consensus target price of $132.57, indicating a potential downside of 3.00%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than GSK.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GSK 1 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.86Insmed 0 Sell rating(s) 1 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 2.94 Which has better valuation and earnings, GSK or INSM? GSK has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGSK$40.10B2.01$3.29B$2.1618.34Insmed$363.71M79.43-$913.77M-$5.71-23.94 Do insiders and institutionals have more ownership in GSK or INSM? 15.7% of GSK shares are owned by institutional investors. 10.0% of GSK shares are owned by company insiders. Comparatively, 3.0% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryGSK beats Insmed on 10 of the 16 factors compared between the two stocks. Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INSM vs. The Competition Export to ExcelMetricInsmedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.80B$3.08B$5.75B$9.82BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-23.8621.1830.8726.51Price / Sales79.43394.02464.97121.10Price / CashN/A44.4437.7659.36Price / Book23.138.1410.186.69Net Income-$913.77M-$54.08M$3.27B$265.51M7 Day Performance3.07%2.97%2.95%3.35%1 Month Performance34.32%4.09%4.16%1.00%1 Year Performance78.58%19.11%45.06%23.48% Insmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INSMInsmed3.7836 of 5 stars$136.02+1.1%$132.57-2.5%+74.5%$28.75B$363.71M-23.821,271GSKGSK2.5746 of 5 stars$39.05-0.8%$37.38-4.3%-9.5%$79.57B$40.10B18.0868,629Trending NewsDividend CutTAKTakeda Pharmaceutical1.3317 of 5 stars$15.18+1.2%N/A-0.6%$48.31B$30.09B50.6147,455ARGXargenex3.0853 of 5 stars$661.32+1.1%$746.81+12.9%+37.0%$40.47B$2.25B33.911,599Trending NewsAnalyst ForecastAnalyst RevisionONCBeOne Medicines1.4279 of 5 stars$319.32-0.6%$330.89+3.6%N/A$35.00B$3.81B-184.5811,000Positive NewsBNTXBioNTech2.8884 of 5 stars$112.55-0.9%$135.80+20.7%+18.3%$27.06B$2.98B-70.346,772TEVATeva Pharmaceutical Industries3.5742 of 5 stars$18.08+1.2%$24.71+36.7%-3.7%$20.74B$16.54B-113.0036,830Positive NewsGap UpSMMTSummit Therapeutics2.2465 of 5 stars$26.28-1.5%$35.00+33.2%+84.2%$19.52BN/A-26.02110Positive NewsAnalyst ForecastGMABGenmab A/S3.5831 of 5 stars$23.42+0.5%$37.60+60.5%-11.2%$15.02B$3.12B11.772,682News CoverageVTRSViatris1.9548 of 5 stars$10.63+0.2%$10.40-2.2%-10.9%$12.39B$14.74B-3.6732,000RDYDr. Reddy's Laboratories2.9393 of 5 stars$14.26+0.2%$16.95+18.9%-13.7%$11.90B$3.81B21.6027,811News CoveragePositive News Related Companies and Tools Related Companies GSK Competitors Takeda Pharmaceutical Competitors argenex Competitors BeOne Medicines Competitors BioNTech Competitors Teva Pharmaceutical Industries Competitors Summit Therapeutics Competitors Genmab A/S Competitors Viatris Competitors Dr. Reddy's Laboratories Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INSM) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access